These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 29167138)

  • 1. Recent advances in management of autosomal-dominant polycystic kidney disease.
    Potts JW; Mousa SA
    Am J Health Syst Pharm; 2017 Dec; 74(23):1959-1968. PubMed ID: 29167138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
    Bennett H; McEwan P; Hamilton K; O'Reilly K
    BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease.
    Chebib FT; Torres VE
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1765-1776. PubMed ID: 30049849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic Kidney/Liver Disease.
    Roediger R; Dieterich D; Chanumolu P; Deshpande P
    Clin Liver Dis; 2022 May; 26(2):229-243. PubMed ID: 35487607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.
    Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG
    Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of the Imaging Techniques for Measuring Kidney and Cyst Volume in Establishing Autosomal Dominant Polycystic Kidney Disease Progression.
    Magistroni R; Corsi C; Martí T; Torra R
    Am J Nephrol; 2018; 48(1):67-78. PubMed ID: 30071518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathophysiology, epidemiology, clinical presentation, diagnosis and treatment options for autosomal dominant polycystic kidney disease].
    Noël N; Rieu P
    Nephrol Ther; 2015 Jul; 11(4):213-25. PubMed ID: 26113401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.
    Rysz J; Gluba-Brzózka A; Franczyk B; Banach M; Bartnicki P
    Expert Opin Pharmacother; 2016 Oct; 17(15):2049-56. PubMed ID: 27650472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-Species Insights into Autosomal Dominant Polycystic Kidney Disease: Provide an Alternative View on Research Advancement.
    Luo J; Zhang Y; Jayaprakash S; Zhuang L; He J
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease.
    Stayner C; Brooke DG; Bates M; Eccles MR
    Curr Med Chem; 2019; 26(17):3081-3102. PubMed ID: 29737248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spanish guidelines for the management of autosomal dominant polycystic kidney disease.
    Ars E; Bernis C; Fraga G; Martínez V; Martins J; Ortiz A; Rodríguez-Pérez JC; Sans L; Torra R;
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv95-105. PubMed ID: 25165191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the Need for Clinical Trial End Points in Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Smith KA; Thompson AM; Baron DA; Broadbent ST; Lundstrom GH; Perrone RD
    Am J Kidney Dis; 2019 Apr; 73(4):533-541. PubMed ID: 30600104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects.
    Saini AK; Saini R; Singh S
    Mol Med; 2020 Dec; 26(1):128. PubMed ID: 33308138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents.
    Reddy BV; Chapman AB
    Pediatr Nephrol; 2017 Jan; 32(1):31-42. PubMed ID: 27034070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic approaches to autosomal dominant polycystic kidney disease.
    LaRiviere WB; Irazabal MV; Torres VE
    Transl Res; 2015 Apr; 165(4):488-98. PubMed ID: 25438190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA; Keating GM
    Drugs; 2015 Oct; 75(15):1797-806. PubMed ID: 26407729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
    Cho Y; Sautenet B; Rangan G; Craig JC; Ong ACM; Chapman A; Ahn C; Chen D; Coolican H; Kao JT; Gansevoort R; Perrone R; Harris T; Torres V; Pei Y; Kerr PG; Ryan J; Gutman T; Howell M; Ju A; Manera KE; Teixeira-Pinto A; Hamiwka LA; Tong A
    Trials; 2017 Nov; 18(1):560. PubMed ID: 29169385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.